Combined Type ADHD Inattention Restlessness and Impulsivity Together

Reviewd By Burton J. Tabaac, MD, FAHA"

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Combined type ADHD means you have a significant pattern of inattentive symptoms along with hyperactive and impulsive symptoms. You may struggle with focus, task starts, follow through, restlessness, interrupting, waiting, emotional reactions and quick decisions. This ADHD presentation can affect school, work, home routines, relationships and safety because several symptom groups appear together.

The clinical wording is often “combined presentation” because ADHD symptoms can shift over time. You may meet criteria for combined presentation at one stage of life, then show a different symptom pattern later. A child may look very active and distracted. A teen may show poor planning, late assignments and impulsive choices. An adult may feel restless inside, miss details and react quickly during stress.

Combined ADHD is diagnosed through a clinical assessment. A clinician looks at symptom history, age of onset, daily impairment, settings affected and other possible causes. Rating scales can help organize information, but they do not diagnose ADHD alone.

A useful care plan looks at both symptom groups. You may need supports for focus and organization, along with supports for restlessness, impulsivity and emotional reactions. Treatment may include medication, therapy, parent training, school support, work planning, sleep care and daily routines.

Fast answer for combined type ADHD

Combined type ADHD is an ADHD presentation where both inattentive symptoms and hyperactive impulsive symptoms are present. You may lose focus, forget tasks, miss details, struggle to finish work, fidget, feel restless, interrupt, talk often or act before pausing.

This presentation can be easy to notice in children when movement and distraction appear together. It can be less obvious in adults because hyperactivity may become inner restlessness. You may still feel driven, impatient or unable to relax, while also struggling with planning and follow through.

Combined ADHD can be treated, but the plan should match your actual daily problems. If missed deadlines are the main issue, planning supports may come first. If impulsive behavior affects safety or relationships, pause skills and closer monitoring may be needed. If school problems are severe, teacher input and formal supports may be part of care.

A clinician should also check sleep, anxiety, depression, trauma, substance use, learning problems, autism, tics and medical issues when relevant. These can affect attention, movement and impulse control, and some can occur with ADHD.

Symptom mix in daily life

Combined ADHD can feel like several problems happening at once. You may forget the task, feel restless while trying to do it, start late, miss details and react strongly when someone points it out. This mix can make daily life feel harder than any single symptom would suggest.

Inattention may show up as lost items, unfinished work, missed instructions, poor organization and task avoidance. You may start a task with good intent, then drift, switch to something else or lose the next step.

Hyperactivity may show up as fidgeting, pacing, talking often or needing frequent movement. In adults, it may feel like inner pressure, mental speed or a need to stay busy.

Impulsivity may show up as interrupting, quick spending, fast driving, sudden decisions, emotional outbursts or messages sent before you have cooled down. You may regret the action soon after, but the pause was missing in the moment.

Combined symptoms often affect relationships. A partner, parent, teacher, friend or coworker may see missed tasks and interruptions as lack of care. A better plan names the specific behavior and adds a practical support, such as written tasks, pause cues or shared routines.

Child, teen and adult examples

Combined ADHD changes with age because demands change. The core pattern may stay present, but it may look different in school, adolescence and adult life.

Children

A child with combined ADHD may lose worksheets, miss instructions, leave a seat, call out answers, interrupt peers and have trouble waiting. Homework may be difficult because the child must sit still, remember instructions, resist distraction and keep working.

At home, you may see intense mornings, bedtime resistance, chore delays and emotional outbursts. The child may want to behave well but struggle to pause, remember steps and stay with the routine.

A child may need parent training, classroom support, behavior planning and clinician review for treatment options. School input is often helpful because teachers can describe attention, movement, peer behavior and work completion.

Teens

A teen with combined ADHD may forget assignments, delay studying, feel bored quickly, act on impulse, struggle with sleep and react strongly during conflict. Driving, substances, screen use and peer pressure may raise safety concerns.

Teens need support that respects growing independence. Useful tools may include written deadlines, phone limits during driving, study blocks, teacher check ins, medication follow up when prescribed and family rules that are clear and consistent.

Adults

Adults with combined ADHD may miss deadlines, switch tasks too often, feel restless in meetings, interrupt, overbook the day, avoid paperwork and feel exhausted from trying to appear organized. You may finish urgent tasks well, then miss routine duties.

Adult care may include medication review, cognitive behavioral therapy, skills training, work planning, sleep care and relationship repair tools. A clinician may also assess anxiety, depression, substance use and sleep problems.

Diagnosis wording and presentation changes

The term “combined type” is widely used, but many clinicians now use “combined presentation.” This wording reflects that ADHD symptoms can change across time. You may have more visible hyperactivity as a child and more inattentive symptoms as an adult. You may also show more symptoms during high stress, poor sleep or higher life demands.

Diagnosis usually requires a persistent symptom pattern that began in childhood and causes impairment. The clinician may ask about home, school, work, relationships, safety, sleep and emotional reactions. For children, teacher reports and caregiver reports are often used together. For adults, childhood history and current impairment are both important.

A diagnosis should not rely only on a checklist. Checklists can help start the assessment, but they cannot rule out other causes. Poor sleep, anxiety, depression, trauma, learning disorders, autism, substance use, thyroid problems and medication effects can all affect focus, activity level and impulse control.

You can prepare by writing down examples. Include missed deadlines, unfinished work, lost items, interruptions, emotional reactions, late arrivals, unsafe choices, school concerns and relationship strain. Clear examples help the clinician see how symptoms affect daily life.

Treatment planning for mixed symptoms

Treatment for combined ADHD should address both attention problems and hyperactive impulsive symptoms. If care focuses only on focus, impulsive reactions may continue. If care focuses only on behavior, task avoidance and disorganization may remain.

Medication can reduce core ADHD symptoms for many people when prescribed and monitored by a qualified clinician. Stimulant and nonstimulant options may be discussed based on age, health history, side effects, sleep, appetite, blood pressure, mood, tics and substance risk.

Therapy can help with task avoidance, planning, emotional reactions and communication. Cognitive behavioral therapy may help adults build work systems and reduce avoidance. Parent training may help caregivers support children through routines, rewards and consistent limits.

School support may include written instructions, movement breaks, teacher check ins, task chunking, seating changes and help turning in completed work. Work support may include written priorities, meeting notes, time blocks and fewer avoidable interruptions.

Daily planning tools can help make tasks visible. You may need one calendar, one task list, timers, a launch spot for important items, written routines and a weekly reset. Impulsivity may need extra guardrails, such as spending limits, delayed send rules for messages and driving phone rules.

Psychedelic research has brought serious scientific attention to emotional processing, therapeutic setting and mental flexibility. For combined ADHD, current care should follow established clinical guidance, and psilocybin is not an approved ADHD treatment.

Related pages for deeper reading

You may need a broader page if you are still learning the basics of ADHD. A general ADHD guide can explain symptoms, diagnosis, treatment, medication, therapy and daily support in one place.

You may need a symptoms page if you are trying to compare inattention, hyperactivity and impulsivity across age groups. This can help you prepare clearer examples for a clinician.

You may need a diagnosis page if you want to know what happens during assessment. This can explain interviews, rating scales, school input, medical review and questions to bring to the visit.

You may need a treatment page if you already have a diagnosis and want to compare medication, therapy, parent training, school help, work planning and daily routines.

Conclusion

As you review combined type ADHD, symptom patterns and current research limits, we at Rose Hill Life Sciences follow related questions through our work as a psychedelic research organization focused on the production and research of Psilocybe cubensis, with our role at the intersection of science and therapeutic integration reflected in our Massachusetts research work.

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.